Analysts’ Recent Ratings Updates for Dermira (DERM)
Several analysts have recently updated their ratings and price targets for Dermira (NASDAQ: DERM):
- 11/9/2017 – Dermira was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
- 11/7/2017 – Dermira had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $41.00 price target on the stock, down previously from $47.00.
- 11/7/2017 – Dermira had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $43.00 price target on the stock, down previously from $46.00.
- 11/6/2017 – Dermira had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock. They wrote, “Positives from the quarter: 1) DERM and UCB (Not Covered) today announced that the companies have agreed to end their development and commercialization agreement for Cimzia in psoriasis so that DERM can focus on the potential launch of DRM04, which is expected in 2H18; we believe that this was the right move for DERM and did not think the Street attributed much value to Cimzia. 2) During the quarter, DERM announced a licensing agreement with Roche (Not Covered) and Genentech (Not Covered) to obtain worldwide rights to Lebrikizumab, a monoclonal antibody targeting interleukin (IL-13), for atopic dermatitis and other indications; we think this opportunity is underappreciated. 3) DERM presented glycopyrronium tosylate (formerly DRM04) data at the 26th European Academy of Dermatology and Venereology (EADV) Congress from September 13-17. 4) DERM announced that the DRM04 filing has been accepted by the FDA, with a PDUFA date of 6/30/18. 5) DERM completed patient enrollment in two DRM01 Phase 3 trials for the treatment of acne vulgaris. Finally, 6) DERM ended the quarter with $662.9MM in cash and equivalents, which should fund operations through 1H19.””
- 9/26/2017 – Dermira had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Shares of Dermira, Inc. (NASDAQ DERM) traded up $0.02 during midday trading on Thursday, hitting $23.97. The stock had a trading volume of 586,700 shares, compared to its average volume of 418,266. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira, Inc. has a 12-month low of $21.35 and a 12-month high of $38.75.
In other Dermira news, CEO Thomas G. Wiggans sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $27.52, for a total transaction of $137,600.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Eugene A. Bauer sold 7,500 shares of the firm’s stock in a transaction on Wednesday, October 11th. The stock was sold at an average price of $30.04, for a total value of $225,300.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,400 shares of company stock worth $822,553. Company insiders own 13.30% of the company’s stock.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.